ArticleWiener klinische Wochenschrift2026
Economic, cultural and social inequalities in potentially inappropriate medication-An Austrian perspective.
Article in Wiener klinische Wochenschrift, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inappropriate prescribing remains a global challenge with implications for patient outcomes and healthcare costs. A recent Danish nationwide study investigated potentially inappropriate medications (PIMs), defined using a modified screening tool of older persons' prescriptions (STOPP)/screening tool to alert to right treatment (START) framework and their associations with socioeconomic and sociocultural factors. The STOPP-defined PIMs, indicating potential overtreatment, were present in 3.1% and strongly associated with lower income, education, limited social support and living alone, while START-defined PIMs (12.5%), reflecting potential undertreatment, showed no such associations. These findings highlight the role of socioeconomic and cultural determinants for obtaining optimal care, even within a universal healthcare system, which minimizes cost-related barriers.This article provides an Austrian perspective on this important topic. Available Austrian (and international) data confirm socioeconomic status as a key driver of polypharmacy and PIM exposure, although patterns vary across regions and populations. Broader evidence links PIMs to higher costs, reduced quality of life and increased hospitalizations. Addressing this complex issue requires multifaceted strategies: strengthening health literacy, educating healthcare professionals and fostering multidisciplinary collaboration, integrating deprescribing into clinical care and targeting vulnerable groups such as those with low socioeconomic status or migration backgrounds. Effective implementation of these measures may improve equity, safety and sustainability in pharmacotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.